Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/203780| Title: | Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration |
| Author: | Díaz González, Álvaro Hernández Guerra, Manuel Pérez Medrano, Indhira Sapena, Víctor Riveiro Barciela, Mar Barreira Díaz, Ana Gómez, Elena Morillas, Rosa M. Barrio, María del Escudé, Laia Mateos, Beatriz Horta, Diana Gómez, Judith Conde, Isabel Ferre Aracil, Carlos El Hajra, Ismael Arencibía, Ana Zamora, Javier Fernández, Ainhoa Salcedo, Magdalena Molina, Esther Soria, Anna Estévez, Pamela López, Carmen Álvarez Navascúes, Carmen |
| Keywords: | Hepatitis Malalties autoimmunitàries Hepatitis Autoimmune diseases |
| Issue Date: | 1-Apr-2023 |
| Publisher: | Wolters Kluwer Health |
| Abstract: | In patients with non-severe acute or chronic autoimmune hepatitis (AIH) without cirrhosis, clinical practice guidelines recommend indistinct use of prednisone or budesonide. However, budesonide is infrequently used in clinical practice. We aimed to describe its use and compare its efficacy and safety with prednisone as first-line options. |
| Note: | Versió postprint del document publicat a: https://doi.org/10.1097/hep.0000000000000018 |
| It is part of: | Hepatology, 2023, vol. 77, num. 4, p 1095-1105 |
| URI: | http://hdl.handle.net/2445/203780 |
| Related resource: | https://doi.org/10.1097/hep.0000000000000018 |
| ISSN: | 1527-3350 |
| Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| HEP-22-0918.R2_Proof_hi.pdf | 1.12 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.